Global Antibacterial Drugs Market 2024–2033

Reports Description

As per the current market research conducted by the CMI Team, the global Antibacterial Drugs Market is expected to record a CAGR of 5.6% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 51.55 billion. By 2032, the valuation is anticipated to reach USD 67.9 billion.

To learn more about this report - request a sample report PDF

Antibacterial drugs can be derived from microorganisms like bacteria or molds, or they can be synthesized from scratch. These medications are designed to either eliminate bacteria or impede their growth. They play a pivotal role in modern healthcare, primarily in the treatment and prevention of infectious diseases, including urinary tract infections caused by bacteria like E. coli, S. aureus, and Streptococcus pyogenes.

In addition to urinary tract infections, antibacterial drugs are instrumental in combating contagious respiratory infections such as influenza (commonly known as the flu) and the common cold. These drugs function by either eradicating the microbes responsible for the infections or inhibiting their proliferation. The significance of antibacterial drugs extends to the treatment of various bacterial infections caused by pathogens like Escherichia coli and Klebsiella pneumonia, among others.

Furthermore, the rising incidence of infectious diseases such as tuberculosis, hepatitis B, leprosy, typhoid, malaria, human immunodeficiency virus infection (HIV/AIDS), and more underscores the crucial role these drugs play in safeguarding public health and driving market growth.

Antibacterial Drugs Market - Significant Growth Factors

The escalating challenge posed by bacterial infections and the rising need for innovative medications to combat bacterial diseases is driving the demand for next-generation antibiotics.

Moreover, the growing prevalence of antimicrobial resistance, primarily stemming from the excessive use of antibacterial treatments, is expected to prompt a shift in prescription practices towards advanced therapies for the management of infectious diseases.

According to data from the Centers for Disease Control and Prevention (CDC), Antimicrobial Resistance (AMR) affects over 2.9 million individuals annually in the United States alone. This substantial burden underscores the pressing demand for antibiotics, driven by a notable increase in the incidence of infectious diseases.

Diarrhea is a prominent cause of child mortality worldwide, as highlighted by the World Health Organization (WHO), necessitating antibiotic interventions to prevent severe illness. The prevalence of various infectious diseases, including pneumonia, lower respiratory infections, and Hospital-Acquired Infections (HAIs), is contributing significantly to the growth of the market.

Furthermore, the growing disease burden is prompting both governmental and non-governmental organizations to invest in research and development (R&D) endeavours aimed at creating novel drugs.

For instance, government agencies like BARDA have partnered with multiple companies to support the development of new therapies for infectious diseases. This collaborative effort is a response to the increasing awareness of antibiotic-resistant infections, prompting pharmaceutical and biopharmaceutical firms to prioritize the creation of combination therapies.

These therapies are designed to yield synergistic and additive effects, offering enhanced efficacy in treating infections. As an example, in March 2022, Venatorx Pharmaceuticals achieved positive clinical phase III results for its combination antibiotic therapy, cefepime-taniborbactam, designed for the treatment of complicated urinary tract infections in adults.

Furthermore, pharmaceutical companies are dedicating more resources to the development of innovative therapies for infectious diseases. According to the Pew Charitable Trust, as of December 2020, nearly 45 promising antibiotic molecules were under investigation for managing severe bacterial infections, reflecting the industry's commitment to addressing this critical healthcare challenge.

Antibacterial Drugs Market - Mergers and Acquisitions

• Pfizer's Acquisition of AstraZeneca's Antibiotics Business (2016): Pfizer, a leading pharmaceutical company, acquired AstraZeneca's antibiotics portfolio, strengthening its position in the antibiotics market. This strategic move allowed Pfizer to expand its antibiotic offerings and enhance its infectious disease portfolio.

• Melinta Therapeutics' Acquisition of Cempra (2017): Melinta Therapeutics, a company specializing in antibiotics, acquired Cempra, a clinical-stage pharmaceutical company. This acquisition bolstered Melinta's antibiotic pipeline and expanded its capabilities in developing antibiotics for bacterial infections.

• Merck's Acquisition of Cubist Pharmaceuticals (2015): Merck, a global pharmaceutical company, acquired Cubist Pharmaceuticals, known for its expertise in antibiotics. This acquisition aimed to diversify Merck's product portfolio and strengthen its presence in the antibiotics market.

• Teva Pharmaceutical's Acquisition of Allergan's Generic Business (2016): Teva Pharmaceutical Industries acquired Allergan's generic drug business, which included a range of antibiotic products. This acquisition allowed Teva to expand its generic antibiotic offerings and global market presence.

• Summit Therapeutics' Acquisition of Discuva (2018): Summit Therapeutics, a biotechnology company, acquired Discuva, a developer of novel antibiotics. This acquisition enriched Summit's antibiotic research and development capabilities, particularly in addressing antibiotic-resistant bacteria.

• Nabriva Therapeutics' Acquisition of Zavante Therapeutics (2018): Nabriva Therapeutics acquired Zavante Therapeutics, a company focused on developing antibiotics for challenging infections. This strategic move bolstered Nabriva's antibiotics portfolio and research pipeline.

• Merck's Acquisition of Peloton Therapeutics (2019): Merck acquired Peloton Therapeutics, which had antibiotic development programs in its pipeline. This acquisition aligned with Merck's commitment to addressing unmet medical needs, including antibiotic-resistant infections.

• Sumitomo Dainippon Pharma's Acquisition of Roivant Sciences (2020): Sumitomo Dainippon Pharma acquired Roivant Sciences, which included Roivant's subsidiary, Myovant Sciences, engaged in antibiotic research and development. This acquisition expanded Sumitomo Dainippon Pharma's presence in the infectious diseases and antibiotics space.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Antibacterial Drugs Market - Significant Threats

• Antimicrobial Resistance (AMR): The development of antimicrobial resistance by bacteria poses a significant threat. Overuse and misuse of antibiotics contribute to the emergence of drug-resistant strains, making it challenging to treat infections effectively.

• Limited Pipeline: The antibiotic development pipeline is relatively limited compared to other therapeutic areas. The high costs and challenges associated with antibiotic research and development have led many pharmaceutical companies to deprioritize this area, potentially resulting in a scarcity of new antibiotics.

• Economic Viability: Antibiotic development faces economic challenges. Short treatment durations and the need for responsible antibiotic stewardship programs can limit the financial returns for pharmaceutical companies, discouraging investment in new antibiotic research.

• Regulatory Hurdles: Regulatory approval processes for antibiotics can be stringent, requiring extensive clinical trials and evidence of safety and efficacy. Meeting these regulatory requirements adds to the cost and time involved in bringing new antibiotics to market.

• Low Pricing: Competitive pricing pressures and the need for affordable antibiotics can lead to lower profit margins for manufacturers, affecting the economic viability of antibiotic production.

• Complexity of Antibiotic Resistance: Bacterial resistance mechanisms are complex and continually evolving. Developing antibiotics that can effectively combat resistant strains is a significant challenge.

• Biosecurity Concerns: The potential misuse or biosecurity threats associated with the development and distribution of antibiotics pose security concerns at a global level.

• Lack of Novel Mechanisms: There is a need for antibiotics with novel mechanisms of action to combat resistant bacteria effectively. The absence of such innovations limits the arsenal of available treatments.

• Global Health Security: Infectious diseases, including those caused by drug-resistant bacteria, can have global health security implications. Outbreaks and pandemics can strain healthcare systems and disrupt economies.

Report Scope

Category-Wise Insights

Based on the Action Mechanism:

In 2022, the cell wall synthesis inhibitor segment dominated the market, commanding a significant share of 53.5%. This substantial market share can be attributed to several factors, including the broad-spectrum action mechanisms exhibited by these antibiotics and their frequent prescription for the treatment of both gram-negative and gram-positive bacterial infections.

Notably, antibiotics like carbapenems, penicillin, and cephalosporins, which fall under the category of cell wall synthesis inhibitors, are among the most commonly used drugs for managing bacterial infections.

Furthermore, the cell wall synthesis inhibitor segment is experiencing growth due to increased research activities and a rising number of regulatory approvals for these antibiotics. These factors collectively contribute to the segment's dominance in the market.

Based on Type:

In 2022, the generic antibiotics segment emerged as the clear leader in the overall market, commanding a substantial revenue share of 81.7%. Furthermore, it is projected to exhibit the most rapid growth rate over the forecast period. Several factors contribute to the dominance of this segment.

Firstly, the widespread adoption of generic antibiotic formulations can be attributed to their affordability. These cost-effective alternatives make antibiotics more accessible to a broader population, thereby increasing their demand and market share. Secondly, the presence of numerous manufacturers in the generic antibiotics segment leads to heightened competition and subsequently empowers buyers with greater bargaining power.

This competitive landscape further enhances the segment's prominence within the market. Moreover, a supportive regulatory framework plays a pivotal role in driving the growth of generic antibiotics. Regulatory agencies facilitate the approval and distribution of generic preparations, encouraging their utilization within the healthcare sector.

Lastly, government initiatives favoring the promotion of generic antibiotic formulations, along with initiatives aimed at enhancing access to generic drugs, are acting as catalysts for the segment's expansion. These combined factors position generic antibiotics as the dominant force within the market.

Antibacterial Drugs Market - Regional Analysis

North America:

• North America, led by the United States and Canada, is a prominent player in the Antibacterial Drugs market. The region benefits from advanced healthcare infrastructure, high healthcare expenditure, and significant investments in research and development.

• Rising concerns about antimicrobial resistance and the need for novel antibiotics drive the demand for antibacterial drugs in North America.

Europe:

• Europe, including countries like the United Kingdom, Germany, and France, is a well-established market for antibacterial drugs. The region's healthcare systems focus on infection control and antibiotic stewardship programs.

• Regulatory agencies, such as the European Medicines Agency (EMA), play a crucial role in approving and monitoring antibacterial drugs.

Asia-Pacific:

• The Asia-Pacific region, particularly countries like China, India, and Japan, presents substantial growth opportunities in the Antibacterial Drugs market. The region's population density and diverse healthcare landscapes contribute to the demand for antibiotics.

• Growing awareness of infectious diseases, improving healthcare infrastructure, and the presence of a vast pharmaceutical manufacturing base are key factors in the market's expansion.

Latin America:

• Latin America is witnessing increased demand for antibacterial drugs, primarily due to a rising burden of infectious diseases. Countries like Brazil and Mexico are significant contributors to market growth.

• Economic disparities and variations in healthcare access across the region influence market dynamics.

Middle East and Africa:

• The Middle East and Africa region exhibit variations in the prevalence of infectious diseases. Some countries face a high burden of bacterial infections, while others have lower rates.

• Efforts to improve healthcare access, combat infectious diseases, and enhance antibiotic availability contribute to market growth.

List of the prominent players in the Antibacterial Drugs Market:

• AbbVie Inc.
• Pfizer Inc.
• Novartis AG
• Merck & Co. Inc.
• Teva Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals Inc.
• Viatris Inc.
• Melinta Therapeutics LLC
• Cipla Inc.
• Shionogi & Co. Ltd.
• KYORIN Pharmaceutical Co. Ltd.
• GSK plc
• Nabriva Therapeutics PLC
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America